• Boston Scientific (Natick, Massachusetts) reported the launch of the Precision Plus spinal cord stimulation system (SCS), a rechargeable SCS neuromodulation device for the treatment of chronic pain of the trunk, back and limbs. Precision Plus provides physicians with EGL scan, the first and only SCS lead scanning technology. The Precision Plus system also features an improved remote control and charger to simplify control of patient therapy. EGL scan (electronically generated lead scan) technology displays the relative position of implanted leads, within seconds and without using fluoroscopy or x-ray. The information from EGL Scan can be used to increase programming accuracy, which can lead to improvements in patient outcomes and treatment office operating efficiencies. One in five Americans suffers the effects of chronic pain, and approximately five million people may be candidates for SCS therapy.

• Ivivi Technologies (Northvale, New Jersey) reported that it has completed enrollment in its clinical trial using the company’s pulsed electromagnetic field (PEMF) technology to treat patients with ischemic cardiomyopathies. The institutional review board (IRB)-approved clinical trial at the Cleveland Clinic is designed for cardiac patients who are not candidates for surgical intervention such as angioplasty, stenting or cardiac bypass surgery. The trial looks at the use of Ivivi’s PEMF technology over a period of five months on patients with ischemic cardiomyopathy, a heart condition characterized by decreased blood flow to the heart. The primary endpoint is the improvement in regional myocardial perfusion (the flow of blood through the heart) and function as seen with a 64-slice computed tomography (CT) Scan. The secondary endpoint is patient improvement for angina and exercise tolerance. Ivivi Technologies specializes in non-invasive electrotherapeutic technology.

• Medtronic (Minneapolis) said that a review of data from the ENDEAVOR IV clinical trial indicates that the trial has met its primary, non-inferiority endpoint. The trial is evaluating the safety and efficacy of the Endeavor drug eluting coronary stent as compared to the Taxus paclitaxel-eluting coronary stent system from Boston Scientific. ENDEAVOR IV has a primary endpoint of target vessel failure (TVF - a composite of cardiac death, myocardial infarction and target vessel revascularization) at nine months. Medtronic will submit these data to the FDA in support of the Endeavor pre-market approval (PMA) application. Medtronic specializes in alleviating pain, restoring health, and extending life.

• Omni-Tract Surgical (St. Paul, Minnesota) reports the introduction of their new GhosTract radiolucent retractor kit. These blades are designed to retract tissue during anterior lumbar spine procedures. Because these procedures access the spine via an incision in the patient’s abdomen, retractors must be used to maintain a pathway to the spine. The most commonly used retractors are stainless steel, which blocks the intra-operative imaging necessary during these procedures. GhosTract retractor blades are designed to be translucent, allowing the X-ray to “see through” the retractor blades. Omni-Tract Surgical makes table-mounted surgical retractors.

• Sequenom (San Diego) and Lenetix Medical Screening Laboratory (Mineola, New York) reported that Lenetix has submitted a clinical package to the New York State Department of Health to support its application for a clinical laboratory permit to perform a non-invasive prenatal Rhesus D (RhD) incompatibility test, the first non-invasive prenatal test based on Sequenom’s Fetal Nucleic Acid Technology. Lenetix’s RhD application of Sequenom’s fetal nucleic acid technology detects a fetus’ RhD status from the mother’s blood sample without invasive procedures that typically pose risk to the health of the mother and baby in utero. Lenetix makes genetic screening and diagnostic testing products.

• Surgical Information Systems (SIS; Atlanta) and Materials Management Microsystems reported the first successful implementation of a bidirectional interface between SIS’ perioperative software solution and the SPM sterile processing information system. The new interface ensures consistency between instrument set descriptions in SPM and in SIS’ preference cards, and provides real-time information on instrumentation requirements necessary for supporting the OR schedule. Efficient and compliant instrument delivery, coordinated with the scheduling function, is an essential component of a streamlined operating room. And because the OR generates the largest revenues and costs in most hospitals, an effective and intuitive interface is of importance. SIS provides surgery management solutions. Microsystems provides bar code driven sterile processing management information systems.